Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Return on Capital Employed (2020 - 2025)

Avidity Biosciences' Return on Capital Employed history spans 6 years, with the latest figure at 0.4% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 15.0% year-over-year to 0.4%; the TTM value through Dec 2025 reached 0.4%, down 15.0%, while the annual FY2025 figure was 0.48%, 10.0% down from the prior year.
  • Return on Capital Employed reached 0.4% in Q4 2025 per RNA's latest filing, down from 0.39% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.2% in Q1 2021 to a low of 0.45% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.34%, with a median of 0.35% recorded in 2024.
  • Peak YoY movement for Return on Capital Employed: decreased -18bps in 2021, then grew 20bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.3% in 2021, then fell by -25bps to 0.37% in 2022, then decreased by -22bps to 0.45% in 2023, then skyrocketed by 44bps to 0.25% in 2024, then tumbled by -60bps to 0.4% in 2025.
  • Per Business Quant, the three most recent readings for RNA's Return on Capital Employed are 0.4% (Q4 2025), 0.39% (Q3 2025), and 0.41% (Q2 2025).